BioNexus Gene Lab Corp. (BGLC) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$282.40K; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$540.49K; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$702.51K; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$611.29K; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$282.40K | (m) | (m) | (m) | $250.00* | -$422.49K* | (m) | $13.67K | (m) | $0.00 |
| 2026-03-31 | Reported | (m) | -$540.49K | (m) | (m) | (m) | $325.00 | -$147.67K | (m) | $14.49K | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$702.51K | (m) | (m) | (m) | $5.48K* | -$1.24M* | (m) | $14.88K | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$611.29K | (m) | (m) | (m) | $21.46K* | -$737.91K* | (m) | $12.56K | (m) | $0.00 |
| 2025-03-31 | Reported | (m) | -$618.42K | (m) | (m) | (m) | $9.05K | -$824.07K | (m) | $12.14K | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$1.34M | (m) | (m) | (m) | $199.19K* | -$1.60M* | (m) | $10.44K | (m) | $1.55K |
| 2024-06-30 | Reported | (m) | $259.17K | (m) | (m) | (m) | $1.83K* | -$672.27K* | (m) | $8.20K | (m) | $55.58K |
| 2024-03-31 | Reported | (m) | -$79.03K | (m) | (m) | (m) | $21.95K | -$37.15K | (m) | $11.47K | (m) | -$20.07K |
| 2023-09-30 | Reported | (m) | -$2.53M | (m) | (m) | (m) | $134.00K* | -$899.35K* | (m) | (m) | (m) | $76.42K |
| 2023-06-30 | Reported | (m) | -$272.20K | (m) | (m) | (m) | $14.36K* | -$23.82K* | (m) | (m) | (m) | $15.99K |
| 2023-03-31 | Reported | (m) | -$50.63K | (m) | (m) | (m) | $102.00 | -$116.52K | (m) | (m) | (m) | -$15.99K |
| 2022-09-30 | Reported | (m) | -$65.22K | (m) | (m) | (m) | $3.66K* | $308.89K* | (m) | (m) | (m) | $10.11K |
| 2022-06-30 | Reported | (m) | -$137.96K | (m) | (m) | (m) | $1.29K* | -$195.97K* | (m) | (m) | (m) | -$1.62K |
| 2022-03-31 | Reported | (m) | $34.69K | (m) | (m) | (m) | $32.19K | -$37.84K | (m) | (m) | (m) | $14.30K |
| 2021-09-30 | Reported | (m) | $372.64K | (m) | (m) | (m) | $410.00* | $315.87K* | (m) | (m) | (m) | $75.17K |
| 2021-06-30 | Reported | (m) | $139.99K | (m) | (m) | (m) | $666.00* | -$905.14K* | (m) | (m) | (m) | $108.28K |
| 2021-03-31 | Reported | (m) | $342.10K | (m) | (m) | (m) | $807.00 | $115.43K | (m) | (m) | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | $237.31K | (m) | (m) | (m) | $0.00* | $754.74K* | (m) | (m) | (m) | -$492.00 |
| 2020-06-30 | Reported | (m) | -$33.97K | (m) | (m) | (m) | -$2.00* | -$157.20K* | (m) | (m) | (m) | $487.00 |
| 2020-03-31 | Reported | (m) | $1.07M | (m) | (m) | (m) | $307.00 | -$977.35K | (m) | (m) | (m) | $860.00 |
| 2019-09-30 | Reported | (m) | -$50.14K | (m) | (m) | (m) | -$3.53K* | -$57.41K* | (m) | (m) | (m) | $28.11K |
| 2019-06-30 | Reported | (m) | -$69.22K | (m) | (m) | (m) | $23.84K* | -$52.94K* | (m) | (m) | (m) | $1.18K |
| 2019-03-31 | Reported | (m) | -$60.20K | (m) | (m) | (m) | -$14.63K | -$48.56K | (m) | (m) | (m) | -$1.26K |
| 2018-09-30 | Reported | (m) | -$55.14K | (m) | (m) | (m) | -$46.81K* | $176.53K* | (m) | (m) | (m) | -$33.82K* |
| 2018-06-30 | Reported | (m) | -$39.47K | (m) | (m) | (m) | (m) | -$20.83K* | (m) | (m) | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$2.97M | (m) | (m) | (m) | $36.97K | -$1.84M | (m) | $50.67K | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$1.57M | (m) | (m) | (m) | $226.99K | -$2.09M | (m) | $47.51K | (m) | -$3.49K |
| 2023-12-31 | Reported | (m) | -$2.59M | (m) | (m) | (m) | $149.40K | -$1.82M | (m) | $54.98K | (m) | -$21.53K |
| 2022-12-31 | Reported | (m) | -$291.18K | (m) | (m) | (m) | $0.00 | $551.82K | (m) | (m) | (m) | -$52.31K |
| 2021-12-31 | Reported | (m) | $1.06M | (m) | (m) | (m) | $3.16K | $9.16K | (m) | (m) | (m) | -$291.28K |
| 2020-12-31 | Reported | (m) | $1.27M | (m) | (m) | (m) | $421.62K | $552.68K | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$275.70K | (m) | (m) | (m) | $12.82K | -$217.27K | (m) | (m) | (m) | $24.76K |
| 2018-12-31 | Reported | (m) | $59.90K | (m) | (m) | (m) | -$39.62K | -$274.08K | (m) | (m) | (m) | -$33.45K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |